Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the transcript. The company remains debt-free as of September 30, 2024, with a cash balance of INR 657 crores. The management discusses growth and capacity expansion primarily through internal accruals, acquisitions (M&A), and organic growth. Talks about looking for value-accretive M&A deals but no concrete plans or targets for fundraising. No indication of raising capital through debt or equity in the near future from the Q2FY25 earnings call.

Any current/future capex/capital investment/strategic investment?

The Teva manufacturing facility is currently operating at 40%-45% capacity with a current run rate of around INR440-450 crores per year. The Teva facility is expected to scale up to a capacity of around INR800 crores, likely by next year. Beyond Teva, the company is exploring further capacity expansion either through new facilities, new blocks, or greenfield projects. The company is actively looking for value-accretive M&A opportunities that are reasonably priced, as they have been cautious with domestic market acquisitions due to high valuations. Capex investments during H1 FY25 were INR76 cr

Future growth expectations in sales/revenue/volumes?

The company aims to achieve INR 3,000 crores in revenue within the next two years, a milestone considered "well within sight." Current run rate is around INR 440-450 crores, with the Teva facility operating at 40-45% capacity; expected to trend toward INR 800 crores by next year. Incremental revenues will come from all plants including Teva and the U.S. facility, with plans to increase product launches and order book size (now standing at $200 million). The U.S. market is a major growth driver, focusing on expanding product portfolios within existing customers rather than adding many new

Future growth expectations in earnings/operating earnings/profits/EPS?

Marksans Pharma targets revenue of INR 3,000 crores within the next 2 years. EBITDA margin expected around 22%, stable with no anticipated cuts. EBITDA for Q2 FY25 was INR 135.7 crores (21.1% margin), with half-year EBITDA at INR 264.1 crores (21.4% margin). Profit after tax for Q2 FY25 was INR 97.8 crores, up 16.6% YoY; half-year PAT at INR 186.8 crores, up 21.1% YoY. EPS for Q2 FY25: INR 2.1; EPS for H1 FY25: INR 4.1. US business order book at $200 million, with expected revenue acceleration in coming years. UK market expected to grow, aiming to be among the top-three companies in 2-3 years.

Current/ Expected Orderbook/ Pending Orders?

Current order book stands at approximately $200 million, showing improvement from the previous range of $170 million to $180 million. The company is building the order book steadily, with quarterly revenue trending around $40 million currently. Many contracts began only in September-October, resulting in a lost first half of the year, but growth is expected to continue as product launches roll out through January to March. A full 12-month cycle of contracts and product launches is needed to realize the order book potential fully. Inventory has been built up in anticipation of these launches an

Marksans Pharma LtdQ2 FY25Pharmaceuticals & Biotechnology

Marksans Pharma Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹315.35P/E: 27.7Market Cap: ₹14.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company aims to achieve INR 3,000 crores in revenue within the next two years, a milestone considered "well within sight."
Current run rate is around INR 440-450 crores, with the Teva facility operating at 40-45% capacity; expected to trend toward INR 800 crores by next year.
Incremental revenues will come from all plants including Teva and the U.S. facility, with plans to increase product launches and order book size (now standing at $200 million).
The U.S. market is a major growth driver, focusing on expanding product portfolios within existing customers rather than adding many new ones.
The UK and Europe markets are expected to grow steadily, with the company targeting top-three player status in the UK within 2-3 years.
Australia & New Zealand market expected to double OTC revenues over time, aiming for AUD 50 million mark as a growth milestone.
Operating leverage benefits expected as Teva facility scales up; freight costs have normalized.

Margin guidance

Category 3

Marksans Pharma targets revenue of INR 3,000 crores within the next 2 years.
EBITDA margin expected around 22%, stable with no anticipated cuts.
EBITDA for Q2 FY25 was INR 135.7 crores (21.1% margin), with half-year EBITDA at INR 264.1 crores (21.4% margin).
Profit after tax for Q2 FY25 was INR 97.8 crores, up 16.6% YoY; half-year PAT at INR 186.8 crores, up 21.1% YoY.
EPS for Q2 FY25: INR 2.1; EPS for H1 FY25: INR 4.1.
US business order book at $200 million, with expected revenue acceleration in coming years.
UK market expected to grow, aiming to be among the top-three companies in 2-3 years.
Australian OTC market expected to grow steadily, potentially doubling revenue over time.
Teva facility utilization presently ~40-45%, with plans to scale capacity to INR 800 crores revenue. Further capacity expansion planned beyond this.

See what Marksans Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or future fundraising through debt or equity in the transcript.
The company remains debt-free as of September 30, 2024, with a cash balance of INR 657 crores.
The management discusses growth and capacity expansion primarily through internal accruals, acquisitions (M&A), and organic growth.
Talks about looking for value-accretive M&A deals but no concrete plans or targets for fundraising.
No indication of raising capital through debt or equity in the near future from the Q2FY25 earnings call.

Order book

Yes

Current order book stands at approximately $200 million, showing improvement from the previous range of $170 million to $180 million.
The company is building the order book steadily, with quarterly revenue trending around $40 million currently.
Many contracts began only in September-October, resulting in a lost first half of the year, but growth is expected to continue as product launches roll out through January to March.
A full 12-month cycle of contracts and product launches is needed to realize the order book potential fully.
Inventory has been built up in anticipation of these launches and order fulfillments, expected to stay elevated till at least March 2025.
The company continues to focus on expanding its portfolio within existing customers to increase order book size rather than adding many new customers.

See what Marksans Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The Teva manufacturing facility is currently operating at 40%-45% capacity with a current run rate of around INR440-450 crores per year.
The Teva facility is expected to scale up to a capacity of around INR800 crores, likely by next year.
Beyond Teva, the company is exploring further capacity expansion either through new facilities, new blocks, or greenfield projects.
The company is actively looking for value-accretive M&A opportunities that are reasonably priced, as they have been cautious with domestic market acquisitions due to high valuations.
Capex investments during H1 FY25 were INR76 crores, aligned with the plan to scale up the acquired Teva facility.
The company is working on its next phase of projects for capacity enhancement or new acquisitions once Teva facility capacity is near full utilization.

Track Marksans Pharma Ltd — get its next earnings analysis in your feed

How does Marksans Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMarksans Pharma Ltd

Rev 2Mar 3

See where Marksans Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Marksans Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Marksans Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Marksans Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →